Link Between Idiopathic Myopathy and Cancer Risk Explored
A new large‑scale cohort study reveals that individuals diagnosed with idiopathic inflammatory myopathy face a significantly heightened risk of developing cancer, particularly within the first two years after diagnosis. The analysis of over 5,000 patients identified a 1.5‑fold increase in overall cancer incidence, with ovarian, lung, and colorectal cancers driving the excess risk. Researchers recommend proactive oncologic screening protocols and multidisciplinary management to mitigate adverse outcomes. The findings clarify a previously ambiguous relationship between muscle disease and malignancy, offering clearer guidance for clinicians.
2026 Cardiovascular Catalysts: Lp(a) on the Horizon
The Phase III HORIZON trial of pelacarsen, an antisense oligonucleotide that lowers lipoprotein(a), will deliver its first readout in early 2026. Ionis Pharmaceuticals and Novartis are awaiting results that could confirm whether Lp(a) reduction translates into fewer heart attacks, strokes, and...
2026 Catalysts: Breakthrough Progress in Renal Disease
Renal disease is emerging as a hotbed for pharmaceutical investment after surrogate endpoints for IgA nephropathy (IgAN) were validated, simplifying trial designs and regulatory reviews. This year’s pipeline sees Phase III results expected from at least two IgAN candidates, with a...
Survey Results: What Sponsors Say Is Slowing Cancer Trials — and What’s Helping
A BioCentury and Advarra survey of oncology sponsors and CROs reveals pervasive operational friction slowing cancer trials. Nearly all respondents report post‑start protocol amendments, which add several months to study timelines and cascade into staffing and data delays. The study...
Aerobic Glycolysis in Schizophrenia: Developmental Rescue or Energetic Breakdown?
Recent research links schizophrenia to a distinct pattern of brain energy metabolism, characterized by elevated lactate, reduced glucose uptake, and mitochondrial oxidative‑phosphorylation deficits. These findings echo the Warburg‑like aerobic glycolysis observed in proliferating cells and suggest a shift toward non‑oxidative...
“SHANK3 Deficiency Alters Early Progenitor Dynamics and Reveals Shared Pathways with Neurodegeneration”
A multi‑institutional study using patient‑derived iPSCs and an isogenic SHANK3‑edited line shows that SHANK3 haploinsufficiency drives transcriptional up‑regulation of cell‑cycle and DNA‑repair pathways, leading to increased progenitor proliferation and neuronal hyper‑connectivity. Bulk RNA‑seq identified 903 differentially expressed genes, with co‑expression...
Splitting Schizophrenia: Divergent Cognitive and Educational Outcomes Revealed by Genomic Structural Equation Modelling
Researchers applied genomic structural equation modelling to separate schizophrenia‑specific genetic risk from the component shared with bipolar disorder. The analysis identified 63 SZ‑specific and 78 shared loci, revealing that SZ‑specific variants are linked to lower educational attainment and reduced fluid...
Neuroinflammation: An Unfortunate Term to Describe Schizophrenia
The article argues that labeling schizophrenia as "neuroinflammation" oversimplifies a complex immune landscape. While genetics, peripheral blood markers, and epidemiology reveal systemic immune abnormalities, brain‑specific inflammatory signatures are inconsistent. Imaging studies of microglial activation and cerebrospinal fluid cytokine analyses show...
Somatostatin-Expressing Neurons in the Zona Incerta Regulate Chronic Stress Response and Modulate Depression-Like Behaviors
Researchers identified somatostatin‑expressing (SOM+) neurons in the zona incerta (ZI) as key regulators of the chronic stress response. Using optogenetic manipulation in mouse models, activation of SOM+ ZI neurons attenuated stress‑induced corticosterone elevation and reduced depression‑like behaviors, while inhibition produced...
Surgical Menopause Care in Bladder Cancer Patients
A recent discussion highlights the need for specialized surgical menopause care in bladder cancer patients, emphasizing hormone management after radical cystectomy. The piece points to gaps in current protocols and calls for multidisciplinary approaches integrating urology, oncology, and gynecology. It...
Validating Phenazine-Producing Rhizobacteria for Sustainable Wheat Protection
Researchers have validated phenazine‑producing rhizobacteria as a biocontrol agent for wheat, demonstrating significant suppression of Fusarium head blight in multi‑location field trials. The bacteria, isolated from native soils, were formulated into a seed coating that reduced disease incidence by up...
Insights From Hepatitis Testing for Steatotic Liver Policy
The article aggregates recent biomedical and agricultural research highlighting advances in genomic profiling, RNA therapeutics, neuroinflammation models, and novel diagnostics. Highlights include genome‑wide SNP arrays for metastasis risk, circular RNA ZFAND6 suppressing gastric cancer spread, and improved hemoglobin testing for...
Improving Acne Detection with Memory Classifiers
The article announces a new approach to acne detection that leverages memory‑based classifiers, a type of AI model that retains contextual information across image sequences. By incorporating temporal memory, the system can differentiate between transient skin changes and true acne...
Gut Microbes Shape Cancer Growth and Immunity Through Asparagine Metabolism
A new study published in Cell Host & Microbe shows that gut bacteria can control cancer progression by modulating asparagine availability. The enzyme‑encoding bo‑ansB gene in Bacteroides ovatus depletes intestinal asparagine, limiting its delivery to tumors and impairing CD8+ T‑cell...
Dual Challenge: Selective IgA Deficiency and Autoimmunity
A recent BMC Pediatrics case study documents a patient with selective Immunoglobulin A (IgA) deficiency who simultaneously developed autoimmune hemolytic anemia. The report details the diagnostic work‑up, highlighting how standard immunoglobulin panels uncovered the dual pathology. Researchers emphasize the rarity...
Tri-Ortho-Cresyl Phosphate: Nephrotoxicity and Oxidative Stress Link
Researchers led by Wang et al. demonstrated that subchronic exposure to tri‑ortho‑cresyl phosphate (TOCP) triggers nephrotoxicity by elevating oxidative stress and inhibiting neuropathy target esterase (NTE). The study details how oxidative imbalance damages renal cells and how NTE inhibition may...
Deep Neural Networks Transform Voxel-Based Morphometry Preprocessing
Deep neural networks are reshaping voxel‑based morphometry (VBM) preprocessing by automating key steps such as bias correction, tissue segmentation, and spatial registration. Early trials show up to a 70% reduction in processing time while preserving or improving segmentation accuracy compared...
Securing Radiopharma and GLP-1 Supply Chains Through 2026 M&A
Bain & Company’s Global M&A Report 2026 reveals pharma’s pivot from pure IP hunting to vertical integration, especially in radiopharma, GLP‑1 obesity treatments, and antibody‑drug conjugates. Deal values rebounded to $4.9 trillion in 2025, with strategic transactions focusing on manufacturing capacity, isotope...
FDA Says It Explained Issues Early on for Corcept's Rejected Cushing's Syndrome Drug
The U.S. Food and Drug Administration issued a formal rejection of Corcept Therapeutics' experimental treatment for Cushing's syndrome, stating that it had raised serious scientific concerns early in the review process. FDA officials say they communicated these issues to Corcept...
Kinetochores Regulate Anaphase Spindle Length via Depolymerization
Researchers have uncovered that kinetochores actively regulate anaphase spindle length by promoting microtubule depolymerization. Live‑cell imaging and laser ablation experiments showed that loss of kinetochore‑mediated depolymerization reduces spindle length by roughly 15‑20 percent. The study identifies the kinesin‑13 family protein...
Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate's ICE Fight
The Senate’s failure to pass the omnibus spending bill left the rare‑pediatric priority review voucher (PRV) program without reauthorization, prompting biotech CEOs to intensify lobbying. Without a renewal, about 200 rare‑disease therapies could lose eligibility, threatening up to $4 billion in...
Vetter Announces Plan to Build Manufacturing Site in Germany with €1.5 Billion CDMO Investment
Vetter Pharma announced a €1.5 billion expansion to build a new commercial sterile‑injectable manufacturing plant in Saarlouis, Germany, slated to create up to 2,000 jobs and begin phased construction in Q2 2026. The investment also includes a clinical production facility in Des Plaines,...
The Pros and Cons of Pesticides and Fertilizers in Real-World Mandarin Orange Farms
Researchers at Japan's RIKEN Center applied inverse probability weighting to data from mandarin orange orchards in 12 prefectures, revealing that cutting chemical pesticides boosts soil microbial diversity but also increases leaf‑pathogen fruit diseases. The analysis showed soil carbon improves when...
Decoding Ashwagandha’s Withanolide Genes via Yeast
Researchers have mapped the complete set of genes responsible for withanolide biosynthesis in Ashwagandha and successfully transferred them into engineered Saccharomyces cerevisiae. The yeast platform produced withanolide A and related compounds at concentrations exceeding 150 mg per liter, a five‑fold improvement over prior...
Bitterroot Reverts to Preclinical Biotech in CD47 as CEO Leaves
Bitterroot Bio, a specialist in CD47 immunotherapy, announced that its program has reverted to the pre‑clinical discovery stage after a brief push toward clinical development. The move coincides with the unexpected resignation of its chief executive officer, raising questions about...
CHMP Opposes Lilly’s Mounjaro in Heart Failure, Backs Novo’s Kayshild
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) voted against extending Eli Lilly’s weight‑loss drug tirzepatide (Mounjaro) to treat heart failure, citing insufficient efficacy data. In the same meeting, the CHMP gave a positive opinion to...
Amgen Gives up on Its Once-Prized Eczema Drug
Amgen has terminated its collaboration with Kyowa Kirin on the OX40‑targeting eczema drug rocatinlimab, returning all rights to the Japanese partner. The decision follows Phase 3 trials that met primary endpoints but failed to demonstrate superiority over established therapy Dupixent and showed...
Ultragenyx Resubmits Gene Therapy for Rare Neuro Disease to FDA
Ultragenyx has re‑submitted its FDA approval request for UX111, an adeno‑associated virus (AAV) gene‑therapy targeting a rare neurodegenerative disease. The company previously faced a complete response letter last summer, prompting additional pre‑clinical work and safety analyses. UX111 aims to replace...
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
The former CytoDyn chief executive was sentenced to 30 months in prison after convictions for securities fraud, wire fraud and insider trading. Meanwhile, major pharmaceutical companies are accelerating AI adoption, signing multi‑billion‑dollar deals with platform providers such as Nvidia and...
Quince's Steroid Therapy for Rare Disease Fails, Shares Tank
Quince Therapeutics announced that its once‑monthly steroid‑based therapy for ataxia‑telangiectasia failed to meet the primary endpoint in a pivotal Phase 3 trial. The rare genetic disorder affects roughly 1 in 100,000 children and currently lacks disease‑modifying treatments. Following the data...
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Moderna has signed a licensing agreement with Italy’s Recordati to transfer a Phase 3 rare‑disease mRNA therapeutic to the European drugmaker. The deal provides Recordati with worldwide commercialization rights, an upfront cash payment estimated at $150 million, and a series of development...
Amgen Ends Partnership with Kyowa Kirin on Immunology Drug, Despite Phase 3 Wins
Amgen abruptly terminated its collaboration with Japan’s Kyowa Kirin on a late‑stage immunology candidate, returning all rights to the partner despite the drug’s recent Phase 3 success. The move aligns with Amgen’s broader strategic shift toward internal R&D priorities and upcoming biosimilar...
Lilly Unveils $3.5B Factory that Will Make Retatrutide and Other Obesity Drugs
Eli Lilly has allocated $3.5 billion to build a new manufacturing complex in Pennsylvania’s Lehigh Valley that will produce its next‑generation obesity injectable retatrutide and related compounds. The plant is designed for flexible, single‑use bioreactor technology and aims to output over a...
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
The FDA released draft guidance urging sponsors of multiple myeloma drugs to use minimal residual disease (MRD) negativity as the primary endpoint for accelerated approval, moving beyond traditional overall response rates. The agency defines MRD‑negative as one cancer cell per...
Polish Nurses’ Evidence-Based Practice: Knowledge and Leadership Insights
Evidence‑based practice (EBP) is essential for modern nursing, linking care decisions to the best research. A cross‑sectional study by Miszewska and Zarzeczna‑Baran surveyed Polish nurses across specialties, revealing a stark split in EBP competence. While a minority demonstrated solid knowledge,...
Long COVID Impact: Ethnic Variations in Symptoms
A recent multinational cohort study reveals pronounced ethnic disparities in long COVID symptom profiles. Black and Hispanic patients report fatigue and neurological complaints at rates significantly higher than White counterparts, even after adjusting for age and comorbidities. Socioeconomic deprivation and...
Resurrecting Ancient Enzymes in NASA’s Search for Life Beyond Earth
NASA‑backed researchers have resurrected a 3.2‑billion‑year‑old nitrogenase enzyme, demonstrating that its nitrogen‑isotope signature remains unchanged despite billions of years of molecular evolution. By reverse‑engineering modern nitrogenase, the team recreated ancestral versions and expressed them in microbes, confirming that the isotopic...
3D Patellar Shape Linked to Dislocation Risk
A new study by Yan, Yao, and Liu demonstrates a direct link between three‑dimensional patellar shape and the likelihood of patellar dislocation. Using automated coordinate algorithms and statistical shape modeling on a diverse cohort, the researchers identified distinct geometric features...
Opentrons Global Robotics Chief, James Atwood, Named Chief Executive Officer
Opentrons Labworks has promoted James Atwood, who has led its Robotics Business Unit since April 2023, to chief executive officer. Under his guidance the company expanded its installed base to more than 10,000 robotic systems deployed worldwide across academia, biotech...
Stable Coacervate Microdroplets as Robust Microreactors for Enhanced Enzymatic Catalysis
Researchers have engineered highly stable coacervate microdroplets using polyethyleneimine (PEI) and sodium thioctate (ST) that resist coalescence for over 35 days without any additives. The droplets exploit electrostatic and hydrophobic interactions, creating a charge‑repelled surface that preserves structural integrity. They...
Multifunctional Biomimetic Hematoma Microspheres for Sustained Local Hydrogen Sulfide (H2S) Delivery to Enhance Vascularized Bone Regeneration
Researchers have engineered biomimetic hematoma microspheres that combine a pH‑responsive GelMA outer layer with a NaHS‑loaded liposomal core to deliver hydrogen sulfide (H₂S) directly to bone defect sites. The microspheres release H₂S in acidic environments, simultaneously reducing chronic inflammation, stimulating...
Alginate/PCL Dressing for Silver Nanoparticle and PDGF-B Delivery
Researchers have engineered an alginate/polycaprolactone (PCL) composite dressing that co‑delivers silver nanoparticles and platelet‑derived growth factor‑B (PDGF‑B). The hybrid matrix provides sustained antimicrobial release while preserving the bioactivity of PDGF‑B to stimulate tissue regeneration. In vivo tests on rodent wound...
Johnson & Johnson’s Pipeline Strategy: What Does 2026 Have in Store for the Big Pharma?
Johnson & Johnson entered 2026 aiming for $100‑$101 billion in sales after a 9.1 % Q4 revenue rise to $24.6 billion. The company is banking on its oncology portfolio—particularly Darzalex, Tecvayli, Carvykti and emerging lung‑cancer combos—to offset the imminent loss of exclusivity for...
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
The White House postponed the rollout of TrumpRx, the federal direct‑to‑consumer drug marketplace. Officials cite potential violations of the federal anti‑kickback statute as a key factor, prompting HHS to issue a guidance bulletin outlining required safeguards. Major manufacturers including Pfizer,...
EMA Looks Into 'Data Integrity' Issue with Amgen's Tavneos
The European Medicines Agency has opened a review into the data integrity of the pivotal ADVOCATE trial that underpinned the EU approval of Amgen’s oral complement C5 inhibitor Tavneos. The regulator’s concerns focus on how the study data were handled...
How Brick-Building Bacteria React to Toxic Chemical in Martian Soil
Researchers at the Indian Institute of Science examined how perchlorate, a toxic chemical in Martian regolith, influences biocementation by a robust native strain of Sporosarcina pasteurii. While perchlorate slows bacterial growth, it triggers extracellular matrix formation that creates microbridges, resulting...
Sorghum Genotypes Show Anthracnose Resistance in Ethiopia
Researchers in Ethiopia identified several sorghum genotypes that exhibit strong resistance to anthracnose, a fungal disease that can devastate yields. Field trials across major growing regions showed up to 20% higher grain production compared with susceptible varieties under disease pressure....
Pinus Nigra’s Defense Mechanisms Against Diplodia Sapinea
Researchers have detailed how Pinus nigra (black pine) resists infection by the fungal pathogen Diplodia sapinea, which causes tip blight and significant timber loss. The study highlights rapid resin exudation, elevated phenolic production, and a coordinated transcriptional shift toward defense...
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
Sanofi announced it has deprioritized its SP0237 mRNA‑based seasonal flu vaccine, removing the candidate from near‑term launch plans. The hexavalent shot was in a Phase I/II safety and immunogenicity trial for adults over 50, which remains active but is not recruiting...
Mosaic’s Nanoneedle Granted Advanced Manufacturing Technology Designation for Gene Therapy Products
The FDA’s Center for Biologics Evaluation and Research granted NanoMosaic an Advanced Manufacturing Technology (AMT) designation for its Nanoneedle platform, which multiplexes vector genome and capsid titer testing in AAV gene‑therapy production. The designation confirms the technology’s ability to streamline...
